MedTrace Logo

Additional KIF6 Risk Offers Better Adherence to Statins

NCT01068834 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1282

Last updated 2012-02-01

No results posted yet for this study

Summary

Many patients prescribed statins to lower their cholesterol stop taking their statin over time. The purpose of this study is to determine whether providing subjects their KIF6 carrier status (associated with increased cardiovascular event risk) will improve adherence to statin medications.

Conditions

Interventions

GENETIC

KIF6 genetic test

KIF6 carrier status with interpretation sheet provided to subject

Sponsors & Collaborators

  • Celera Genomics

    collaborator INDUSTRY

  • Medco Health Solutions, Inc.

    lead INDUSTRY

Principal Investigators

  • Scott L Charland, PharmD · Medco Health Solutions, Inc.

  • James J Devlin, PhD · Celera Genomics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-04-30
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01068834 on ClinicalTrials.gov